Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: GSK.LSE
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

GSK (GSK) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

2,055 GBX

+9.5%+13.8% incl. dividends

2031

5-Year

BUY

2,650 GBX

+41.2%+71.7% incl. dividends

Published batch insight

Specialty Pipeline Acceleration Shields Biopharma Cash Flows Against Imminent Generic Patent Cliff

There is high consensus that specialty biopharma expansion and structural cost-reduction programs will defend operating margins against upcoming late-decade patent expirations. Robust free cash flow and resolved litigation provide defensive stability, though divergence persists regarding pipeline replacement velocity and debt servicing costs during generic erosion.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Universal Investor (Polymath), Machiavelli (Insider), Superintelligence (Anthropologist), Michael Burry (Vulture), Elon Musk (Visionary), Sherlock Holmes (Whistleblower), J.P. Morgan (Titan), Warren Buffett (Value Purist), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in GSK at the forecast anchor (2026-09-18): $16,952 in five years versus $13,892 for S&P 500 benchmark.

GSK · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 4.0% net dividend yield for GSK.

Figure: Five-year synthesized consensus value path for GSK compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in GBX; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 1,877.5 GBX1-year price return: +9.46%5-year price return: +41.15%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in GBX, with returns and rationale
Quarter	Target (GBX)	Quarter return	Total return	Forecast rationale
Q4 2026	1,923.28	+2.44%	+2.44%	Third-quarter results confirm robust specialty medicine growth and seasonal vaccine distribution. Initial cost savings from Accelerate Growth and regulatory clarity on acquired oncology assets support positive sentiment, enabling modest valuation multiple expansion despite elevated interest rates.
Q1 2027	1,968.88	+2.37%	+4.87%	Full-year 2026 financial reporting delivers core operating profit at the guided upper bound alongside dividend reaffirmation. Commercial traction for long-acting HIV regimens and resolved litigation liabilities encourage institutional capital accumulation, driving steady equity appreciation.
Q2 2027	2,016.89	+2.44%	+7.42%	First-quarter disclosures showcase strong international vaccine expansion and oncology adoption, offsetting mature respiratory pricing pressure. Resilient operating cash flow comfortably absorbs integration costs and debt servicing, maintaining positive share price momentum across European markets.
Q3 2027	2,055.11	+1.90%	+9.46%	Interim Phase III readouts for bepirovirsen and depemokimab provide positive clinical validation. Although summer vaccine seasonality and elevated clinical trial expenditure temporarily moderate operating leverage, underlying equity sentiment remains well defended by defensive prescription cash flows.
Q4 2027	2,098.56	+2.11%	+11.77%	Accelerate Growth achieves its initial annualized cost reduction milestones, buffering operating margins. Expanding patient adoption of Cabenuva and Apretude reinforces visibility ahead of upcoming patent transitions, driving defensive institutional inflows into year-end portfolio positioning.
Q1 2028	2,131.34	+1.56%	+13.52%	Full-year 2027 results confirm mid-single-digit constant currency revenue expansion and healthy free cash flow conversion. Management provides confident guidance for the impending patent cliff, reassuring income-focused investors and sustaining stable valuation multiples.
Q2 2028	2,102.92	-1.33%	+12.01%	Initial US loss of exclusivity on oral dolutegravir prompts predictable headline sentiment caution and targeted generic discounting. However, accelerated conversion to long-acting regimens and rising oncology revenues cushion the financial impact, preventing severe multiple de-rating.
Q3 2028	2,132.96	+1.43%	+13.61%	Second-quarter metrics confirm that specialty medicines and depemokimab uptake effectively mitigate oral HIV generic erosion. Realized restructuring savings protect core operating profitability, prompting value-oriented buyers to step in and stabilize quoted equity valuations.
Q4 2028	2,177.45	+2.09%	+15.98%	Cumulative annualized restructuring savings surpass one billion pounds, structurally protecting operating margins against generic pricing pressure. Regulatory approvals for new oncology indications expand commercial visibility, reigniting positive share momentum heading into the fiscal year-end.
Q1 2029	2,205.86	+1.30%	+17.49%	Full-year 2028 financial delivery demonstrates that core operating profits remained resilient through early generic competition. Evidence of effective patent cliff absorption dismantles the terminal value-trap narrative, driving institutional short covering and solid multiple expansion.
Q2 2029	2,231.91	+1.18%	+18.88%	European dolutegravir patent expirations take effect but encounter minimal commercial disruption due to established injectable market share. Continued scaling of acquired lung cancer therapies preserves group gross margins, maintaining orderly, positive share price discovery.
Q3 2029	2,262.31	+1.36%	+20.50%	Mid-year clinical updates showcase favorable registrational endpoints across respiratory biologics and next-generation mRNA vaccines. High-margin specialty turnover exceeds half of group sales, proving management's strategic portfolio transformation and supporting steady equity compounding.
Q4 2029	2,317.47	+2.44%	+23.43%	Full realization of the targeted £1.9 billion annual cost savings permanently optimizes operational overhead. Surging cash generation from commercial oncology blockbusters accelerates balance-sheet deleveraging, reinforcing investor confidence in corporate capital allocation execution.
Q1 2030	2,369.33	+2.24%	+26.20%	Full-year 2029 reporting corroborates margin defense above thirty percent despite peak generic dolutegravir exposure. The board signals an impending resumption of share repurchases, prompting broad institutional accumulation and sustained valuation multiple expansion.
Q2 2030	2,414.69	+1.91%	+28.61%	Commercial rollout of next-generation combination therapies broadens leadership in specialty infectious diseases. Strong operating leverage from rationalized biomanufacturing enhances net income conversion, supporting steady equity gains across global healthcare portfolios.
Q3 2030	2,460.45	+1.90%	+31.05%	Pivotal Phase III data for ultra-long-acting HIV prevention regimens cement multi-year therapeutic dominance, neutralizing generic copycats. Market sentiment responds to structural innovation capability, driving multiple re-rating toward international specialty pharmaceutical peer medians.
Q4 2030	2,510.60	+2.04%	+33.72%	Specialty medicines and vaccines contribute over two-thirds of group revenue, while balance-sheet deleveraging concludes successfully. Surging free cash flow comfortably covers progressive dividend increases and active buybacks, driving robust year-end equity performance.
Q1 2031	2,562.49	+2.07%	+36.48%	Full-year 2030 audited financials confirm group revenue firmly tracking toward long-term corporate turnover milestones. Core earnings expand at high single digits, validating multi-year margin resilience and driving comprehensive sell-side earnings estimate upgrades.
Q2 2031	2,605.68	+1.69%	+38.78%	Expanding international market penetration across emerging vaccine markets sustains durable top-line compounding. With the patent cliff fully absorbed, defensive asset qualities and dependable cash distributions attract steady institutional capital inflows.
Q3 2031	2,650.10	+1.70%	+41.15%	Final forecast period consolidates the five-year transformation into a high-margin specialty biopharma compounder. The market closes the historical valuation discount, pricing the equity at full parity with global pharmaceutical leaders to complete the investment cycle.

The fundamental investment case centers on an operational bridge: high-margin Specialty Medicines expansion and £1.9 billion in structural cost extraction via the Accelerate Growth initiative insulate consolidated operating profitability as oral dolutegravir approaches loss of exclusivity between 2028 and 2030. Valuation remains anchored at a pronounced discount to global biopharmaceutical peers, supported by a resilient free cash flow yield and post-Zantac balance sheet normalization. The pivotal risk is whether clinical reinvestment and £7.1 billion in net acquisition debt sufficiently yield commercial blockbusters before generic erosion permanently compresses legacy ViiV Healthcare earnings.

Key insights

Long-acting antiretroviral conversions structurally transform transactional pill demand into sticky outpatient administration networks, preserving unit pricing power despite small-molecule oral generic availability.
Aggressive external business development elevates balance-sheet leverage, shifting intermediate capital allocation priorities away from discretionary share repurchases toward non-discretionary debt amortization and clinical funding.
Restructuring savings function primarily as an operational buffer against statutory payer price concessions rather than delivering net margin windfalls to equity holders.

Deep Dive

External market commentary and prevailing sell-side coverage treat the company as an entrenched, low-multiple value trap. The dominant public belief assumes that the looming 2028 dolutegravir patent expiration will trigger an insurmountable earnings contraction that maturing specialty drugs cannot offset. Investors remain heavily anchored on historical litigation concerns, post-pandemic vaccine slowdowns, and clinical trial attrition, pricing the equity at an enduring valuation discount to international peers.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates fundamental value, creating observable underpricing across the equity. The market misinterprets the approaching dolutegravir patent cliff as an unmitigated revenue collapse, overlooking that rapid patient migration toward long-acting injectable regimens and high-margin oncology launches actively builds an earnings replacement moat. Furthermore, consensus models fail to credit the £1.9 billion Accelerate Growth restructuring, which defends core operating margins above 30%. The strongest challenge remains clinical trial execution risk and elevated debt servicing costs from recent acquisitions.

Repricing catalyst

Pivotal Phase III clinical trial readouts and regulatory decisions across 2026 and 2027 represent the primary catalyst cluster forcing market repricing. Accelerated commercial uptake for depemokimab alongside registrational progress for bepirovirsen and acquired lung cancer assets will demonstrate tangible pipeline replacement power. If consecutive quarterly reports verify that specialty volume gains and restructuring savings defend operating profit ahead of 2028 patent expiries, institutional investors will be forced to dismantle the punitive value-trap discount.

Published consensus context

Macro regime alignment

The macroeconomic backdrop is a net favorable setup. Inelastic prescription demand for essential therapies and vaccines protects revenue against stagflationary pressures. While restrictive interest rates elevate debt servicing expenses following recent acquisitions, robust free cash flow cushions financing burdens, positioning the company as an attractive defensive haven against broader equity volatility.

Published consensus context

Advisor disagreement

The central debate revolves around the velocity of pipeline replacement versus the severity of oral dolutegravir generic erosion. Optimistic perspectives assume that rapid long-acting HIV conversions, specialty oncology scaling, and £1.9 billion in restructuring savings will seamlessly offset patent expirations, justifying significant multiple expansion. Conversely, skeptical viewpoints argue that clinical attrition, £7.1 billion in acquisition debt, and US statutory pricing caps will leave an unfillable earnings void, keeping the equity trapped at discounted multiples. Auditing reported core operating margins through the initial 2028 generic launch window will empirically resolve this economic tension.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Long-acting HIV franchise regimen conversion: ViiV Healthcare is systematically transitioning patients from daily oral dolutegravir to long-acting injectables Cabenuva and Apretude. This clinical migration creates formidable switching barriers, preserving premium pricing and extending specialty franchise revenue beyond upcoming oral patent expiries. Sustained double-digit adoption protects high-margin operating cash flows and defends group earnings. Expected impact: +18%.
Specialty oncology and immunology portfolio expansion: Accelerating momentum across specialty oncology therapies, including Jemperli, Ojjaara, and acquired targeted kinase inhibitors, establishes a vital replacement growth pillar. Complemented by the launch of ultra-long-acting respiratory biologic depemokimab, these proprietary treatments generate superior gross margins exceeding 75%, effectively replacing mature medicine revenue decay and driving core earnings compounding. Expected impact: +18%.
Accelerate Growth restructuring margin protection: Management's Accelerate Growth initiative extracts £1.9 billion in net annual structural operating savings by 2029 across administrative and procurement infrastructure. By trimming overhead, this program cushions operating profitability against loss-of-exclusivity margin compression. Captured efficiencies self-fund twenty concurrent Phase III trial campaigns, ensuring resilient core earnings per share delivery. Expected impact: +13%.
Adult vaccine franchise demographic expansion: Aging global demographics provide a persistent secular tailwind for core immunization assets Shingrix and Arexvy. Expanding international market distribution and broader adult cohort recommendations leverage proprietary adjuvant technology. High biologic manufacturing hurdles and entrenched government procurement relationships generate defensible, high-margin cash streams that insulate top-line revenue from broader macroeconomic cycles. Expected impact: +11%.

Top frictions and headwinds

Dolutegravir loss of exclusivity cliff: Approaching primary patent expirations for oral dolutegravir between 2028 and 2030 threaten ViiV Healthcare's highest-margin revenue generator. Exposed oral combinations face aggressive generic price discounting across core Western jurisdictions. While long-acting formulations provide meaningful mitigation, small-molecule volume defection will inevitably contract franchise gross margins and impose an unavoidable top-line earnings drag. Expected impact: -17%.
US statutory drug price negotiation: Medicare price negotiation protocols and statutory rebate caps under federal healthcare legislation systematically compress net realized prices across mature respiratory and specialty medications. Mandatory manufacturer discounts restrict domestic commercial pricing flexibility, widening gross-to-net deductions. This institutional payer pushback suppresses realized operating cash flows, dampening revenue trajectory in the most lucrative pharmaceutical market. Expected impact: -9%.
Leverage expansion from debt-financed acquisitions: Funding the £7.1 billion net cash acquisition of Nuvalent elevated group debt into an environment of restrictive global interest rates. Elevated debt servicing obligations absorb significant operating cash flow, moderating free cash conversion. This financial commitment temporarily constrains discretionary share repurchase capacity, forcing management to prioritize balance-sheet deleveraging over enhanced capital distributions. Expected impact: -8%.
Vaccine competitive crowding and regulatory constriction: Arexvy and Shingrix confront decelerating growth curves as initial high-risk patient cohorts mature across Western healthcare markets. Narrowed advisory committee recommendations and intensifying rivalry from alternative RSV vaccines restrict volume expansion. Heightened commercial marketing and detailing outlays compress vaccine segment operating leverage, capping prospective incremental returns on invested commercial capital. Expected impact: -8%.

Tail risks

Pivotal Phase III oncology and immunology trial failure: Unexpected clinical failures or safety halts across flagship late-stage programs, including acquired lung cancer assets or Blenrep confirmatory trials, would destroy post-cliff growth projections. Following the camlipixant write-down, major pipeline setbacks would trigger multi-billion-pound non-cash impairment charges. The inability to replace expiring dolutegravir revenues would expose the company to severe generic erosion, prompting sharp valuation multiple de-rating. Probability: +29%. Expected impact: -22%.
Premature dolutegravir patent invalidation rulings: Adverse judicial decisions in Hatch-Waxman patent litigation invalidating secondary crystalline or combination formulation patents could trigger generic dolutegravir launches up to two years ahead of schedule. An accelerated loss of exclusivity would evaporate high-margin oral revenues before long-acting regimens and specialty pipelines attain commercial scale. The sudden cash-flow void would impair dividend coverage and trigger abrupt institutional equity liquidation. Probability: +23%. Expected impact: -21%.

Tail opportunities

Bepirovirsen chronic hepatitis B functional cure approval: Definitive Phase III clinical readouts establishing unprecedented functional cure efficacy for antisense oligonucleotide bepirovirsen could secure expedited global regulatory approvals by 2028. Successfully targeting a global chronic hepatitis B population exceeding 250 million patients would create a multi-billion-pound commercial franchise. This breakthrough would completely dismantle dolutegravir patent cliff concerns, catalyzing rapid multiple expansion and substantial upward revisions to outer-year earnings. Probability: +34%. Expected impact: +24%.
Ultra-long-acting HIV self-administration monopoly: Clinical breakthroughs enabling four-month and six-month self-administered subcutaneous HIV maintenance regimens before 2029 would establish insurmountable therapeutic dominance. Converting patients to biannual home maintenance would preempt oral generic competition entirely and accelerate pre-exposure prophylaxis market adoption. The resulting high-margin cash flows would secure long-term franchise longevity, prompting sovereign and institutional re-rating toward premium global biopharma valuations. Probability: +29%. Expected impact: +21%.

What to monitor

Thesis watchpoints

-- Specialty Medicines sustaining organic revenue growth above 10% CER through mid-2027 confirms pipeline replacement momentum ahead of patent expirations.

Key insights

Core operating margin falling below 27% during fiscal 2027 indicates restructuring savings cannot offset generic pricing erosion and trial reinvestment.
Any adverse judicial ruling invalidating secondary Dovato formulation patents before 2028 demands immediate reassessment of terminal cash-flow models.

Company Financial Analysis

GSK Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

The company's core business continues to perform solidly, driven by strong prescription sales in specialty medicines and adult vaccines. In fiscal 2025, revenue reached £32.7 billion with underlying operating profit expanding steadily. This operational momentum confirms that day-to-day healthcare demand remains reliable and growing. However, headline reported profits experience periodic swings from non-cash accounting adjustments, including a £1.3 billion write-down on a discontinued trial medicine. These paper charges temporarily obscure robust underlying cash generation. With normalized annual free cash flow remaining near £6 billion, the business generates ample liquidity to self-fund its operations.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	GBP 32.7B	GBP 5.7B	GBP 6B
2024	GBP 31.4B	GBP 2.6B	GBP 3.6B
2023	GBP 30.3B	GBP 4.9B	GBP 4.4B
2022	GBP 29.3B	GBP 15B	GBP 5.1B
2021	GBP 24.7B	GBP 4.4B	GBP 5B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	13.0x	TTM	Native	GBX / GBP
2024	21.7x	TTM	Native	GBX / GBP
2023	12.1x	TTM	Native	GBX / GBP
2022	3.9x	Annual	Native	GBX / GBP
2021	9.6x	Annual	Native	GBX / GBP

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Profitability has structurally improved because the company sells an increasing proportion of complex specialty therapies and proprietary vaccines. Gross profit margins expanded above 72% in fiscal 2025, reflecting pricing strength and manufacturing efficiencies that help counteract rising supply chain expenses. To defend profitability against future generic competition, management is executing a restructuring plan targeting £1.9 billion in annual cost savings by 2029. By streamlining administration and commercial operations, these efficiencies ensure core operating margins remain stable near 30% even as older medications face lower generic prices.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	GBP 7.2B	21.9%	17.5%
2024	GBP 5.7B	18.0%	8.2%
2023	GBP 7B	23.1%	16.2%
2022	GBP 6.7B	22.8%	51.0%
2021	GBP 5.4B	21.9%	17.8%

Balance sheet and leverage

AI Review

The company's financial foundation has grown considerably safer following the resolution of nearly all major state lawsuits over heartburn medication. Debt levels remain prudent relative to the company's size, and annual earnings cover interest payments more than eleven times over, easily satisfying credit rating agencies. Recent debt issued to finance the £7.1 billion net acquisition of a cancer specialist has increased total borrowing. Nevertheless, strong annual operating cash flow approaching £9 billion comfortably supports regular interest obligations. This financial resilience allows management to protect dividend distributions while gradually paying down acquisition debt.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	GBP 17.7B	GBP 3.2B	GBP 14.6B net debt	0.82x
2024	GBP 17B	GBP 3.7B	GBP 13.3B net debt	0.78x
2023	GBP 18B	GBP 5B	GBP 15.3B net debt	0.88x
2022	GBP 21B	GBP 7.7B	GBP 17.5B net debt	0.91x
2021	GBP 24.2B	GBP 4.1B	GBP 20.1B net debt	0.79x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management has deliberately shifted its investment focus away from physical factories and toward discovering and developing new medicines. While physical facility spending consumed just over 4% of revenue, research and development spending surged past £7.5 billion in fiscal 2025 to advance over twenty late-stage clinical programs. This elevated research intensity represents an essential strategic commitment to invent replacement treatments before older drugs lose patent protection. In addition, the company committed substantial capital to acquire targeted lung cancer therapies. While this aggressive reinvestment temporarily limits surplus cash, it constructs high-barrier intellectual property essential for future growth.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	GBP 1.3B	GBP 7.5B
2024	GBP 3B	GBP 5.5B
2023	GBP 2.3B	GBP 5.2B
2022	GBP 2.3B	GBP 4.8B
2021	GBP 2.9B	GBP 4.4B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	BUY	274	+14.2%	Not available	ORIGINAL
5Y	BUY	207	+72.9%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	1,915.05	1,923.1	1,933.83	14
+6M	March 18, 2027	1,895.15	1,976.66	2,011.18	14
+9M	June 18, 2027	1,970.95	2,021.8	2,071.51	14
+1Y	September 18, 2027	2,012.34	2,060.8	2,112.94	14
+15M	December 18, 2027	2,052.39	2,101.83	2,197.46	14
+18M	March 18, 2028	2,011.34	2,131.96	2,263.39	14
+21M	June 18, 2028	1,930.89	2,112.2	2,218.12	14
+2Y	September 18, 2028	1,872.96	2,140.08	2,262.48	14
+27M	December 18, 2028	1,872.96	2,185.07	2,352.98	14
+30M	March 18, 2029	1,891.69	2,221.75	2,470.63	14
+33M	June 18, 2029	1,853.86	2,244.8	2,495.33	14
+3Y	September 18, 2029	1,835.32	2,276.12	2,570.19	14
+39M	December 18, 2029	1,872.03	2,331.66	2,647.3	14
+42M	March 18, 2030	1,890.75	2,386.08	2,753.19	14
+45M	June 18, 2030	1,928.56	2,430.67	2,835.79	14
+4Y	September 18, 2030	1,947.85	2,476.08	2,892.5	14
+51M	December 18, 2030	1,967.33	2,526.43	2,979.28	14
+54M	March 18, 2031	2,006.67	2,579.69	3,068.66	14
+57M	June 18, 2031	2,026.74	2,622.59	3,130.03	14
+5Y	September 18, 2031	2,047.01	2,666.05	3,192.63	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Frozen comparison context

GBPUSD.FOREX forecast context

The batch's original direct_listing_to_usd path is preserved for transparent interpretation of USD-normalized returns.

FX snapshot: 1.34 on September 20, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 20, 2026	1.3132	1.3237	1.34
+6M	March 20, 2027	1.2869	1.3096	1.3534
+9M	June 20, 2027	1.2741	1.3087	1.3669
+1Y	September 20, 2027	1.2613	1.3116	1.3669
+15M	December 20, 2027	1.2487	1.3089	1.3806
+18M	March 20, 2028	1.2362	1.3071	1.3801
+21M	June 20, 2028	1.2239	1.3128	1.3939
+2Y	September 20, 2028	1.2361	1.3158	1.4078
+27M	December 20, 2028	1.2359	1.3139	1.4078
+30M	March 20, 2029	1.2361	1.309	1.3937
+33M	June 20, 2029	1.2357	1.3128	1.4076
+3Y	September 20, 2029	1.2234	1.3138	1.4081
+39M	December 20, 2029	1.2234	1.3168	1.4222
+42M	March 20, 2030	1.2236	1.3159	1.4222
+45M	June 20, 2030	1.2232	1.3216	1.4364
+4Y	September 20, 2030	1.211	1.3218	1.4507
+51M	December 20, 2030	1.211	1.3189	1.4362
+54M	March 20, 2031	1.1993	1.3198	1.4506
+57M	June 20, 2031	1.2109	1.3236	1.4506
+5Y	September 20, 2031	1.1991	1.3227	1.4506

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

Across the independent submissions, an empirically grounded consensus confirms that robust cash generation, structural Zantac litigation de-risking, and favorable product mix in Specialty Medicines provide strong near-term earnings resilience. However, correlated assumptions emerge regarding the seamless replacement of dolutegravir cash flows, where several reports aggressively model rapid multiple expansion despite unavoidable generic pricing deflation between 2028 and 2030. The strongest credible contrarian case highlights that late-stage clinical attrition and elevated debt service from the debt-funded Nuvalent acquisition could coincide with generic erosion, squeezing free cash flow. Reports demonstrating forensic accounting discipline—explicitly modeling Nuvalent interest dilution, statutory US drug price negotiation impacts, and the net delivery of the £1.9 billion Accelerate Growth restructuring—are awarded top relative weights. Conversely, reports projecting aggressive multiple expansion above 16 times earnings without addressing patent cliff reinvestment costs receive downward adjustments to prevent correlated over-optimism.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight14.3/100

The highest quality submission, providing unmatched empirical rigor across verified financial statements, Nuvalent dilution sequencing, and CMS drug price negotiation mechanics. Its balanced thesis rejects speculative multiple expansion, anchoring returns in cash generation and disciplined reinvestment, justifying the top relative weight.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight11.4/100

Distinguished by exceptional forensic fidelity, this analysis integrates SEC filings, bond issuances for Nuvalent, and the expiration of US trade and tariff agreements. Its measured baseline projection properly links financing costs to per-share metrics, justifying a high relative weight.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight9.5/100

A highly rigorous submission grounded in primary filings, this report cogently evaluates the Accelerate Growth cost-out versus oral HIV generic erosion. It balances pipeline optionality with realistic clinical attrition. A higher weight reflects thorough evidence synthesis and sound causal consistency.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight8.6/100

This report systematically evaluates the central macro and micro trade-offs, particularly how the three-year restructuring initiative shields operating margins against generic pricing pressure. A well-earned above-average weight rewards explicit mechanism tracing, realistic rate sensitivity, and rigorous cash-flow scrutiny.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight7.6/100

Offering a disciplined balance-sheet assessment, this analysis highlights the 7.5% free cash flow yield and conservative valuation floor. It captures post-Zantac settlement clarity while prudently evaluating late-stage clinical trials. A solid weight rewards causal rigor and defensible cash-flow expectations.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight7.6/100

Providing an incisive evaluation of post-Zantac legal de-risking and long-acting HIV switching kinetics, this report appropriately models the margin-protective effect of Accelerate Growth. A robust weight reflects causal consistency, high evidence quality, and balanced assessment of Phase III development risks.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight7.6/100

Exhibiting solid grounding in clinical trial milestones and commercial uptake dynamics for depemokimab and Blenrep, this analysis avoids extreme multiple assumptions. A solid allocation reflects disciplined examination of operational leverage and realistic appraisal of competitive threats in respiratory biologics.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight5.7/100

This report details operational mechanics under Luke Miels and the Nuvalent integration, but relies on somewhat optimistic multiple re-rating assumptions despite looming dolutegravir loss of exclusivity. A moderate weight reflects solid clinical analysis tempered by aggressive terminal valuation projections.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight5.7/100

The analysis effectively captures the patient transition from oral dolutegravir to long-acting Cabenuva and Apretude. However, it slightly understates the near-term interest drag from acquisition debt and statutory US pricing headwinds. A standard allocation is justified by coherent free cash flow modeling.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight4.8/100

This analysis presents the strongest contrarian case, modeling severe oral HIV revenue loss and capital misallocation risks. While its skepticism regarding pipeline replacement velocity is valuable, its extreme multiple compression overlooks verified restructuring savings and long-acting conversion defensibility, warranting a measured conservative weighting.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight4.8/100

Focusing on durable owner earnings and wide biological moats in vaccines, this analysis provides sound long-term reasoning. However, it somewhat minimizes statutory US pricing pressures and post-acquisition debt absorption. A calibrated baseline weight reflects strong capital return analysis balanced against execution uncertainties.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight4.8/100

This report accurately identifies the market's overreaction to patent expiries relative to non-discretionary healthcare demand. However, its factor impacts and path assumptions are somewhat generic across the middle forecast quarters. A standard weight captures its valuation floor insights while avoiding correlated overemphasis.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight3.8/100

While offering detailed pipeline tracking for bepirovirsen and Blenrep, this perspective incorporates an excessively optimistic expansion trajectory toward 57% gains that minimizes generic pricing destruction. A trimmed weight prevents double-counting bullish assumptions unsupported by conservative payer and reimbursement realities.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight3.8/100

This perspective offers valuable forensic tracking of restructuring milestones, but projects aggressive multiple expansion and a 70% return path that underweights dolutegravir margin contraction. A reduced weight incorporates its operational insights while discounting its outlier valuation scenario.

Skip to references

Research Provenance

References & Context

This GSK consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 81 deduplicated sources retained for this batch.

01Selected Drugs and Negotiated Prices | CMScms.gov
02Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
03GSK plc - Form 6-K - FY2026sec.gov
04GSK plc - Form 6-K - FY2026sec.gov
05GSK plc - Form 6-K - FY2026sec.gov
06GSK plc - Form 6-K - FY2026sec.gov
07GSK stock gains on USD 750 million blood cancer drug deal and analyst upgradesad-hoc-news.de
08GSK stock steady as RBC starts coverage and Q2 2026 figures reshape outlookad-hoc-news.de
09GSK PLC Earnings - Analysis & Highlights for Q1 2026alpha-sense.com
10GSK Names Luke Miels as Next Chief Executive Officer | Contract Pharmacontractpharma.com
11GSK Q2 Earnings Call Highlights - Daily Politicaldailypolitical.com
12GSK plc (GSK): SWOT Analysis [Apr-2026 Updated]dcf-analysis.com
13Which blockbuster is GSK gunning for next? CEO Miels is looking to oncologyfiercebiotech.com
14GSK PLC (GSK) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Accelerated Pipeline ...finance.yahoo.com
152025 Annual Reportgsk.com

And 66 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: GBP, GBX, USD (quote GBX; primary reporting GBP; converted/valuation USD; normalization GBP).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.